Blakkisrud, J. (2021) “Myelosuppression in patients treated with 177Lutetium-lilotomab satetraxetan can be predicted with absorbed dose to the red marrow as the only variable”, Acta Oncologica, 60(11), pp. 1481–1488. doi: 10.1080/0284186X.2021.1959635.